Luspatercept/Lenalidomide Combo Demonstrates Safety and Early Efficacy in Lower-Risk, Non-Del(5q) MDS
OncLive,
MDS | Maris– stock.adobe.com The combination of lenalidomide (Revlimid) and luspatercept-aamt (Reblozyl) demonstrated safety…
A Multicenter, Phase Ib/II Study That Combines Luspatercept and Lenalidomide (L2) in Lower-Risk, Non-Del(5q) Patients with Myelodysplastic Syndromes: Phase Ib Results
Overview of attention for article published in Blood, November 2024
Altmetric Badge
About this Attention Score
-
In the top 25% of all research outputs scored by Altmetric
-
Good Attention Score compared to outputs of the same age (78th percentile)
-
Above-average Attention Score compared to outputs of the same age and source (61st percentile)
Readers on
- mendeley
- 2 Mendeley